Looks like we've now got an experienced science team to push...

Looks like we've now got an experienced science team to push this study to success, get it up and running and showcase results. Good.

Seemingly no dmd deals until after tox study, at which point we may not want one. So what is Anthony trying to sell, LC? LMGD could certainly have a deal around it generating the ten or tens of millions we need to keep CRs at bay. Then theres this combo study that could certainly have legs with a big player, but it looks like we want all of the US and EU to ourselves.

I like CGs comments around the industry acknowledging inflammation needs controllimg and GT drugs themselves dont stop this as inflammation keeps coming.

I like the (once a distant hope) now real likelyhood of accellerated approval in the US.

I like the non ambulant plus ambulant market remarks also.

I dont like the UKs lack of progress and wonder whats going on there, hopefully its about to move ahead.

If we get the entire US and EU market, all ages, this is a $20 stock min.